Based on our findings of suppression of pancreatic cancer, and inhibition of AKT pathway and induction of JNK pathway mediated by rhoifolin, we further verified whether rhoifolin could influence pancreatic cancer progression by changing the expression of AKT or JNK pathways. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.